Next generation biologics company Noveome Biotherapeutics will evaluate its lead programme ST266 as a potential treatment of severe cytokine storm response associated with Covid-19.
ST266, which was initially developed by Noveome for ophthalmology indications, is a first-of-its-kind cell-free platform biologic drug, composed of hundreds of anti-inflammatory proteins, known as the secretome.
The proteins are collected from donated, full term caesarean-sectioned placentas, which are normally discarded after birth. In clinical trials to date, ST266 has shown to be safe and effective at reducing inflammatory response in humans.